IBDEI06A ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6121,2)
 ;;=^5015680
 ;;^UTILITY(U,$J,358.3,6122,0)
 ;;=N13.8^^39^434^21
 ;;^UTILITY(U,$J,358.3,6122,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6122,1,3,0)
 ;;=3^Urinary Obstruction
 ;;^UTILITY(U,$J,358.3,6122,1,4,0)
 ;;=4^N13.8
 ;;^UTILITY(U,$J,358.3,6122,2)
 ;;=^5015588
 ;;^UTILITY(U,$J,358.3,6123,0)
 ;;=R33.8^^39^434^22
 ;;^UTILITY(U,$J,358.3,6123,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6123,1,3,0)
 ;;=3^Urinary Retention,Unspec
 ;;^UTILITY(U,$J,358.3,6123,1,4,0)
 ;;=4^R33.8
 ;;^UTILITY(U,$J,358.3,6123,2)
 ;;=^5019331
 ;;^UTILITY(U,$J,358.3,6124,0)
 ;;=R39.15^^39^434^24
 ;;^UTILITY(U,$J,358.3,6124,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6124,1,3,0)
 ;;=3^Urinary Urgency
 ;;^UTILITY(U,$J,358.3,6124,1,4,0)
 ;;=4^R39.15
 ;;^UTILITY(U,$J,358.3,6124,2)
 ;;=^5019345
 ;;^UTILITY(U,$J,358.3,6125,0)
 ;;=R39.12^^39^434^25
 ;;^UTILITY(U,$J,358.3,6125,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6125,1,3,0)
 ;;=3^Weak Urinary Stream
 ;;^UTILITY(U,$J,358.3,6125,1,4,0)
 ;;=4^R39.12
 ;;^UTILITY(U,$J,358.3,6125,2)
 ;;=^5019342
 ;;^UTILITY(U,$J,358.3,6126,0)
 ;;=R80.9^^39^434^16
 ;;^UTILITY(U,$J,358.3,6126,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6126,1,3,0)
 ;;=3^Proteinuria,Unspec
 ;;^UTILITY(U,$J,358.3,6126,1,4,0)
 ;;=4^R80.9
 ;;^UTILITY(U,$J,358.3,6126,2)
 ;;=^5019599
 ;;^UTILITY(U,$J,358.3,6127,0)
 ;;=D51.8^^39^435^2
 ;;^UTILITY(U,$J,358.3,6127,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6127,1,3,0)
 ;;=3^Anemia,Vitamin B12 Deficiency
 ;;^UTILITY(U,$J,358.3,6127,1,4,0)
 ;;=4^D51.8
 ;;^UTILITY(U,$J,358.3,6127,2)
 ;;=^5002288
 ;;^UTILITY(U,$J,358.3,6128,0)
 ;;=D52.9^^39^435^1
 ;;^UTILITY(U,$J,358.3,6128,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6128,1,3,0)
 ;;=3^Anemia,Folate Deficiency
 ;;^UTILITY(U,$J,358.3,6128,1,4,0)
 ;;=4^D52.9
 ;;^UTILITY(U,$J,358.3,6128,2)
 ;;=^5002293
 ;;^UTILITY(U,$J,358.3,6129,0)
 ;;=I10.^^39^436^12
 ;;^UTILITY(U,$J,358.3,6129,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6129,1,3,0)
 ;;=3^Hypertension,Essential
 ;;^UTILITY(U,$J,358.3,6129,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,6129,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,6130,0)
 ;;=I15.0^^39^436^13
 ;;^UTILITY(U,$J,358.3,6130,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6130,1,3,0)
 ;;=3^Hypertension,Renovascular
 ;;^UTILITY(U,$J,358.3,6130,1,4,0)
 ;;=4^I15.0
 ;;^UTILITY(U,$J,358.3,6130,2)
 ;;=^5007071
 ;;^UTILITY(U,$J,358.3,6131,0)
 ;;=I13.11^^39^436^8
 ;;^UTILITY(U,$J,358.3,6131,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6131,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 5 Chr Kidney/ESRD
 ;;^UTILITY(U,$J,358.3,6131,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,6131,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,6132,0)
 ;;=I13.2^^39^436^7
 ;;^UTILITY(U,$J,358.3,6132,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6132,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 5 Chr Kidney/ESRD
 ;;^UTILITY(U,$J,358.3,6132,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,6132,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,6133,0)
 ;;=I70.1^^39^436^3
 ;;^UTILITY(U,$J,358.3,6133,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6133,1,3,0)
 ;;=3^Atherosclerosis of Renal Artery
 ;;^UTILITY(U,$J,358.3,6133,1,4,0)
 ;;=4^I70.1
 ;;^UTILITY(U,$J,358.3,6133,2)
 ;;=^269760
 ;;^UTILITY(U,$J,358.3,6134,0)
 ;;=I77.3^^39^436^2
 ;;^UTILITY(U,$J,358.3,6134,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6134,1,3,0)
 ;;=3^Arterial Fibromuscular Dysplasia
 ;;^UTILITY(U,$J,358.3,6134,1,4,0)
 ;;=4^I77.3
 ;;^UTILITY(U,$J,358.3,6134,2)
 ;;=^5007812
 ;;^UTILITY(U,$J,358.3,6135,0)
 ;;=E26.02^^39^436^5
 ;;^UTILITY(U,$J,358.3,6135,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6135,1,3,0)
 ;;=3^Glucocorticoid-Remediable Aldosteronism
 ;;^UTILITY(U,$J,358.3,6135,1,4,0)
 ;;=4^E26.02
 ;;^UTILITY(U,$J,358.3,6135,2)
 ;;=^329904
 ;;^UTILITY(U,$J,358.3,6136,0)
 ;;=I12.9^^39^436^14
 ;;^UTILITY(U,$J,358.3,6136,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6136,1,3,0)
 ;;=3^Hypertensive CKD Stage 1-4
 ;;^UTILITY(U,$J,358.3,6136,1,4,0)
 ;;=4^I12.9
 ;;^UTILITY(U,$J,358.3,6136,2)
 ;;=^5007066
 ;;^UTILITY(U,$J,358.3,6137,0)
 ;;=I12.0^^39^436^15
 ;;^UTILITY(U,$J,358.3,6137,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6137,1,3,0)
 ;;=3^Hypertensive CKD Stage 5 or ESRD
 ;;^UTILITY(U,$J,358.3,6137,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,6137,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,6138,0)
 ;;=I13.0^^39^436^6
 ;;^UTILITY(U,$J,358.3,6138,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6138,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 1-4 Chr Kidney
 ;;^UTILITY(U,$J,358.3,6138,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,6138,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,6139,0)
 ;;=I13.10^^39^436^9
 ;;^UTILITY(U,$J,358.3,6139,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6139,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 1-4 Chr Kidney
 ;;^UTILITY(U,$J,358.3,6139,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,6139,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,6140,0)
 ;;=I15.1^^39^436^11
 ;;^UTILITY(U,$J,358.3,6140,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6140,1,3,0)
 ;;=3^Hypertension Secondary to Oth Renal Disorders
 ;;^UTILITY(U,$J,358.3,6140,1,4,0)
 ;;=4^I15.1
 ;;^UTILITY(U,$J,358.3,6140,2)
 ;;=^5007072
 ;;^UTILITY(U,$J,358.3,6141,0)
 ;;=I15.2^^39^436^10
 ;;^UTILITY(U,$J,358.3,6141,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6141,1,3,0)
 ;;=3^Hypertension Secondary to Endocrine Disorders
 ;;^UTILITY(U,$J,358.3,6141,1,4,0)
 ;;=4^I15.2
 ;;^UTILITY(U,$J,358.3,6141,2)
 ;;=^5007073
 ;;^UTILITY(U,$J,358.3,6142,0)
 ;;=I50.1^^39^436^16
 ;;^UTILITY(U,$J,358.3,6142,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6142,1,3,0)
 ;;=3^Left Ventricular Failure
 ;;^UTILITY(U,$J,358.3,6142,1,4,0)
 ;;=4^I50.1
 ;;^UTILITY(U,$J,358.3,6142,2)
 ;;=^5007238
 ;;^UTILITY(U,$J,358.3,6143,0)
 ;;=E26.09^^39^436^17
 ;;^UTILITY(U,$J,358.3,6143,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6143,1,3,0)
 ;;=3^Primary Hyperaldosteronism,Other
 ;;^UTILITY(U,$J,358.3,6143,1,4,0)
 ;;=4^E26.09
 ;;^UTILITY(U,$J,358.3,6143,2)
 ;;=^5002735
 ;;^UTILITY(U,$J,358.3,6144,0)
 ;;=I15.8^^39^436^18
 ;;^UTILITY(U,$J,358.3,6144,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6144,1,3,0)
 ;;=3^Secondary Hypertension,Other
 ;;^UTILITY(U,$J,358.3,6144,1,4,0)
 ;;=4^I15.8
 ;;^UTILITY(U,$J,358.3,6144,2)
 ;;=^5007074
 ;;^UTILITY(U,$J,358.3,6145,0)
 ;;=E27.5^^39^436^1
 ;;^UTILITY(U,$J,358.3,6145,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6145,1,3,0)
 ;;=3^Adrenomedullary Hyperfunction
 ;;^UTILITY(U,$J,358.3,6145,1,4,0)
 ;;=4^E27.5
 ;;^UTILITY(U,$J,358.3,6145,2)
 ;;=^5002744
 ;;^UTILITY(U,$J,358.3,6146,0)
 ;;=E26.01^^39^436^4
 ;;^UTILITY(U,$J,358.3,6146,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6146,1,3,0)
 ;;=3^Conn's Syndrome
 ;;^UTILITY(U,$J,358.3,6146,1,4,0)
 ;;=4^E26.01
 ;;^UTILITY(U,$J,358.3,6146,2)
 ;;=^329905
 ;;^UTILITY(U,$J,358.3,6147,0)
 ;;=I15.9^^39^436^19
 ;;^UTILITY(U,$J,358.3,6147,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6147,1,3,0)
 ;;=3^Secondary Hypertension,Unspec
 ;;^UTILITY(U,$J,358.3,6147,1,4,0)
 ;;=4^I15.9
 ;;^UTILITY(U,$J,358.3,6147,2)
 ;;=^5007075
 ;;^UTILITY(U,$J,358.3,6148,0)
 ;;=B20.^^39^437^3
 ;;^UTILITY(U,$J,358.3,6148,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6148,1,3,0)
 ;;=3^HIV Disease
 ;;^UTILITY(U,$J,358.3,6148,1,4,0)
 ;;=4^B20.
 ;;^UTILITY(U,$J,358.3,6148,2)
 ;;=^5000555
 ;;^UTILITY(U,$J,358.3,6149,0)
 ;;=J18.9^^39^437^6
 ;;^UTILITY(U,$J,358.3,6149,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6149,1,3,0)
 ;;=3^Pneumonia,Unspec Organism
 ;;^UTILITY(U,$J,358.3,6149,1,4,0)
 ;;=4^J18.9
 ;;^UTILITY(U,$J,358.3,6149,2)
 ;;=^95632
 ;;^UTILITY(U,$J,358.3,6150,0)
 ;;=J10.1^^39^437^1
 ;;^UTILITY(U,$J,358.3,6150,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6150,1,3,0)
 ;;=3^Flu w/ Respiratory Manifestations
 ;;^UTILITY(U,$J,358.3,6150,1,4,0)
 ;;=4^J10.1
 ;;^UTILITY(U,$J,358.3,6150,2)
 ;;=^5008151
